23rd Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production

Published Apr 01, 2026

Length 573 Pages

SKU # DFAQ21477000

Description

2026 23rd Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production is the most recent study of biotherapeutic developers and contract manufacturing organizations’ current and projected future capacity and production. This report’s 570+ pages of data-rich analysis will help improve your decision-making in biomanufacturing operations, with in-depth analysis of capacity, production trends, benchmarks, and much more.

In-depth analysis and summary of the key survey findings, trends and implications for industry-wide biomanufacturing capacity and biotherapeutic production. Comparison of production by biotherapeutic developers and contract manufacturing organizations. Current and future potential industry bottlenecks. 23 years of trend analysis; part of a series of annual biopharmaceutical manufacturing industry evaluations. This edition includes the joint industry expertise from BioPlan Associates, and many industry consultants and experts.

METHODOLOGY

CHAPTER 0: DEMOGRAPHICS
KEY TAKEAWAYS
INTRODUCTION: Analysis of Average Single-use Bioreactor Size; Analysis of Average Stainless Steel Bioreactor Size
CHAPTER 1: INTRODUCTION AND DISCUSSION: 1-1 SECTOR AND MARKET OVERVIEW; The Industry Continues to Mature; M&A Activities; “Biopharmaceutical:” - The Definition Used Here; Contract Manufacturing Trends; 1-2 BIOPHARMACEUTICAL INDUSTRY STATUS AND MARKET TRENDS; U.S. Healthcare is Changing; Bioprocessing is Increasing Internationally; 1-3 PHARMA INDUSTRY IS SHIFTING TO BIOPHARMACEUTICALS; 1-4 GLOBAL BIOPHARMACEUTICAL MARKET TRENDS; Growth in Biopharmaceutical Product Sales is Increasing the Demand for Bioprocessing; Overall Health of the Biopharmaceutical Sector; U.S. Industry Leadership Continues; Biopharmaceuticals in the Rest-of-the-World; 1-5 BIOPHARMACEUTICAL MARKETS BY PRODUCT CLASS; Monoclonal Antibodies (mAbs) are the Leading Product Class; Monoclonals are a Costly Treatment; 1-6 ANIMAL DERIVED PRODUCTS AND BIOPHARMACEUTICALS; Animal Derived Products and Biopharmaceuticals; Plant-based Biopharmaceutical Manufacturing; 1-7 FUTURE TRENDS IN THE BIOPHARMACEUTICAL INDUSTRY; Future Trends in Biopharma; Conclusion
CHAPTER 2: FUTURE OF BIOPROCESSING: EXPERTS’ PERSPECTIVE: 2-1 2025 FDA Biopharmaceutical Approvals: Promising Year for Novel Biologics Driven by Innovation and Targeted Therapies; 2-2 Recent Transactions Affecting the CDMO Landscape in 2025; 2-3 Artificial Intelligence in Biopharmaceutical Development, Manufacturing, and Quality; 2-4 Vein-to-Vein Manufacturing: Why Cell Therapy Requires a Patient-Centric Compliance Model; 2-5 Can CDMOs Meet the Demand for Capacity in Peptide and Oligonucleotide Therapeutics Manufacturing?
CHAPTER 3: TRENDS AND EMERGING TECHNOLOGIES: KEY TAKEAWAYS; 3-1 INDUSTRY TRENDS IN 2025; Background and Definitions; 3-2 BIOPROCESSING IMPROVEMENTS NEEDED IN 2026; Bioprocessing Improvements Most Needed; Novel Bioprocessing Systems/Innovations; Novel Bioprocessing Systems/Innovations, Biomanufacturers vs. CMOs; 3-3 OPERATIONAL CHANGES IN PRE- AND POST-COVID; Operational Changes Due to Recent Global Economics; Operational Changes (2010 – 2012, 2022-2026); Operational Changes: Biomanufacturers vs. CMOs; Operational Changes: U.S. vs. Western Europe; 3-4 BUDGET ISSUES IN 2026; Biomanufacturers’ Budget Shifts in 2026; Budget Change Comparisons (2009-2026); 3-5 TOP BIOPROCESSING BUDGET EXPENDITURES; New Expenditures Focus Areas in 2026; Top New Bioprocessing Budget Expenditures (2020-2026); 3-6 NEW BIOPROCESSING PRODUCTS DEVELOPMENT OPPORTUNITIES (2026); Upstream New Product Areas of Interest, 2026; Trends: Upstream New Product Areas of Interest (2010-2026); Downstream New Product Areas of Interest, 2026; Analysis Of Key Finding: Demand for New Product Development in Upstream Bioprocessing; Trends: Downstream New Product Areas of Interest (2010-2026) Other General New Product Areas of Interest, 2026; Trends: Other General New Product Areas of Interest (2010-2026); New Product Development Areas: Biomanufacturers vs. CMOs; New Product Development Areas: U.S. vs. Western Europe and ROW; 3-7 FACTORS IN BIOMANUFACTURING CREATING IMPROVEMENTS; Factors in Biomanufacturing Performance Creating “Significant” or “Some” Improvements, 2026; Factors Improving Biomanufacturing Performance (2010-2015, 2025-2026); Factors Improving Biomanufacturing Performance, Biotherapeutic Developers vs. CMOs; Factors Improving Biomanufacturing Performance, U.S. vs. Western Europe vs. ROW; 3-8 COST-CUTTING ACTIONS & DEVELOPMENT TIMELINES; Cost-Cutting Changes: Actions Undertaken During 2011-2016, 2019-2024; Cost-Cutting Changes: Specific to Outsourcing; Factors Impacting Reduction in Cost of Goods (2020-2024); 3-9 AVERAGE COST PER GRAM RECOMBINANT PROTEIN; Distribution, Average Cost per Gram for PRIMARY Recombinant Protein, 2026; Distribution, Average Cost per Gram for PRIMARY Recombinant Protein (2017-2026); Analysis of Key Finding: Some Good from the Pandemic. Cost per Gram in Biomanufacturing Proteins dropped 10% annually during COVID; 3-10 ASSAY DEVELOPMENT; Biomanufacturing Assay Areas Required; Biomanufacturers vs. CMOs; Biomanufacturing Assay Areas Required, U.S. vs Western Europe; 3-11 SELECTING AND PURCHASING COMMERCIAL-SCALE BIOREACTORS; Largest Commercial-Scale Bioreactor Expected in Next Two Years (2022); Top Options for Bioreactor Platforms at Commercial Scale; Top Options for Bioreactor Platforms at Commercial Scale (2021-2024); Largest Single-Use Bioreactor Capacity to Purchase in Next Two Years (2022, 2025-2025); Largest Stainless Steel Bioreactor Capacity Purchase in ‘Next Two Years’, 2022, 2025-2026; 3-12 DISCUSSION: INDUSTRY TRENDS AND ISSUES; Industry Growth and Adaptation; Cost Cutting Trends; Discussion of Cost per Gram; Discussion of Maturity of Single Use
CHAPTER 4: CAPACITY UTILIZATION: KEY TAKEAWAYS; 4-1 CAPACITY UTILIZATION TRENDS; Capacity Utilization Definitions; Relevance of Capacity Utilization; Capacity Utilization in Other Industries, 2026: US Federal Reserve Board Comparisons; Capacity Utilization in Biomanufacturing by System, 2026; Capacity Utilization Changes (2006-2026); Average Growth Rate in Capacity Utilization (2006-2026); 4-2 CAPACITY UTILIZATION: BIOMANUFACTURERS VS. CMOS; Capacity Utilization By System, Biomanufacturers vs. CMOs, 2026; 4-3 CAPACITY UTILIZATION: U.S. VS. WESTERN EUROPEAN; MANUFACTURERS; Capacity Utilization, By System, U.S. vs. Western Europe; Historical 14-year US vs. EU Trends in Capacity Utilization; 4-4 RESPONDENTS’ CURRENT TOTAL PRODUCTION CAPACITY; Mammalian Cell Culture Capacity; Microbial Fermentation Capacity; Cell Therapy Capacity; Gene Therapy Capacity; 4-5 GLOBAL BIOREACTOR CAPACITY; The Largest Capacity Facilities; Biopharmaceutical Capacity Expansions Continue; Biopharmaceutical Developers/Manufacturers as CMOs; Major CMOs in Terms of Facilities and Capacity; 4-6 RANGE OF TITERS WITH MAB PRODUCTION; Distribution of mAb Titer Ranges; Annual mAb Titer Changes (2008-2026); 4-7 DISCUSSION: CAPACITY AND INDUSTRY TRENDS; The Risks of Biomanufacturers Seeking to Become a CMO Future Capacity Trends
CHAPTER 5: CURRENT AND FUTURE CAPACITY CONSTRAINTS AND QUALITY FACTORS: KEY TAKEAWAYS; 5-1 CURRENT CAPACITY CONSTRAINTS; Background & Definitions; ©2026 BIOPLAN ASSOCIATES, INC. • NO UNAUTHORIZED REPRODUCTION PERMITTED • ALL RIGHTS RESERVED xiii; TABLE OF CONTENTS / FIGURES AND TABLES; Current Capacity Constraints; Respondents’ Perception of Capacity Constraints (2004-2026); Differences in Capacity Constraints: Biomanufacturers vs. CMOs; Capacity Constraints: U.S. vs. Western European Biomanufacturers & CMOs; 5-2 EXPECTED CAPACITY CONSTRAINTS; Respondents’ Expectations of Capacity Constraints in Five Years (2031); Expected Capacity Constraints Five-year Projections (2004-2026); Expected Capacity Constraints in Five Years: Biomanufacturers vs. CMOs (2031).215; Expected Capacity Constraints in Five Years: U.S. vs. Western Europe (2031); 5-3 FACTORS IMPACTING FUTURE PRODUCTION CAPACITY; Factors Creating Future Capacity Constraints in Five Years (2031); Factors Creating Future Capacity Constraints (2008-2026); Factors Creating Future Capacity Constraints: Biomanufacturers vs. CMOs; CMO Capacity Bottleneck Projections, in Retrospect; Factors Creating Capacity Constraints: U.S. vs. Western Europe Respondents; 5-4 KEY AREAS TO ADDRESS TO AVOID FUTURE CAPACITY CONSTRAINT; Areas to Avoid Capacity Constraints in 2026; Areas to Avoid Capacity Constraints: Changing Perspectives (2006-2026); Key areas to Address to Avoid Capacity Constraints; Biomanufacturers vs. CMOs.233; Key Areas to Address to Avoid Capacity Constraints: U.S. vs. Western Europe; 5- 5 BATCH FAILURES IN BIOPHARMACEUTICAL MANUFACTURING; Background and Definitions; Average Time Between Batch Failures (2009-2026); Batch Failure Frequency Distribution (2009-2026); Primary Cause of Batch Failures, Percentages of Failures; Primary Cause of Batch Failures, Percentages of Failures for Commercial Manufacturing (2009-2026); Primary Cause of Batch Failures, Percentages of Failures for Clinical Scale Manufacture (2009-2026); Improving Failure Rates; 5-6 QUALITY PROBLEMS IN BIOMANUFACTURING ATTRIBUTED TO VENDORS.249; Global Quality Supply Management (2011-2013, 2022-2023) – 2023 Data; Global Quality Supply Management Biomanufacturers vs. CMOs (2023); U.S. vs. W. Europe Global Quality Supply Management (2023); Addressing Supply Chain Security Post Pandemic; 5-7 DISCUSSION: INDUSTRY TRENDS; Mitigation Strategies for Financial Constraints in Biomanufacturing; Automation and Artificial Intelligence to Address Capacity Constraints
CHAPTER 6: PLANNED FUTURE CAPACITY EXPANSIONS: KEY TAKEAWAYS; 6-1 PLANNED FUTURE CAPACITY EXPANSIONS; Background and Definitions; Industry Average Planned Production Increases, Five Years Estimates (2031); Planned Future Capacity Expansions: Five Year Estimates (2009-2031); Planned Future Capacity Expansions of >100%, by Systems; 6-2 PLANNED FUTURE CAPACITY EXPANSIONS FOR BIOMANUFACTURERS VS CMOS, BY SYSTEM; Planned Future Capacity Expansions for Biomanufacturers vs. CMOs,; Five Year Estimates (2031); 6-3 PLANNED FUTURE CAPACITY EXPANSIONS FOR U.S. VS. WESTERN EUROPE, BY SYSTEM; Planned Future Capacity Expansions for U.S. vs. W. Europe Manufacturers, Five Year Estimates (2031); 6-4 PLANNED FUTURE CAPACITY EXPANSIONS; Biomanufacturing Capacity Under Active Construction in 2026; 6-5 DISCUSSION: FUTURE OF CAPACITY EXPANSION TRENDS; Drivers of Platform-specific Capacity Expansion
CHAPTER 7: OUTSOURCING TRENDS IN BIOPHARMACEUTICAL MANUFACTURING: KEY TAKEAWAYS; 7-1 BACKGROUND AND DEFINITIONS; Why Outsource?; Strategic Manufacturing Planning; Future Projections; 7-2 CURRENT OUTSOURCING BY PRODUCTION SYSTEM; Facilities Currently Outsourcing Production by System (2026); Facilities Currently Outsourcing No Production (All Production “In-house”) (2006-2026); Historical Trends in Outsourcing Production; 7-3 FUTURE OUTSOURCING; Biotherapeutic Developers’ Outsourcing, 5-Year Projections, by System (2031); Five Year Projections for Biomanufacturers Outsourcing Some Production; 7-4 OUTSOURCED ACTIVITIES IN BIOPHARMACEUTICAL MANUFACTURING; Biomanufacturers Outsourcing Some Activity Today, 2026; Comparison of Biomanufacturers’ Outsourcing, (2010-2026); Increased Outsourced Activities, 24-Month Projections; Outsourcing Activities Projected at ‘Significantly Higher Levels’ (2010-2026); Percentage of Activities Outsourced Today, 2026; Comparison of Outsourcing Activities (2010-2026); Change in Average Spending on Outsourcing Activities; Change in Average Spending on Outsourcing by Facilities (2013-2026); 7-5 CRITICAL OUTSOURCING ISSUES; Key Attributes CMOs Must Deliver their Clients; Selecting a CMO, 2006-2018, 2025-2026; Proximity of CMOs to the Client; 7-6 CMOS’ PROBLEMS WITH THEIR CLIENTS; CMOs Problems with Their Clients; 7-7 COUNTRY SELECTIONS FOR INTERNATIONAL OUTSOURCING (OFFSHORING) OF BIOMANUFACTURING; U.S. BioSecure Act Impact on Offshoring (2025 data); USA as Likely for INTERNATIONAL (non-US respondents) Outsourcing Over Next Five Years; Possible” Selections for International Outsourcing (Offshoring) of Biomanufacturing, Over Five Years (2016-2026); U.S.-based Companies “Possible” Outsourcing Destinations; U.S.-based Companies “Likely” Outsourcing Destinations; W. European – based Companies “Possible” Outsourcing Destinations; W. European – based Companies “Likely” Outsourcing Destinations; 7-8 OFFSHORING TRENDS TO LOWER-COST REGIONS; 5-Year Projection for Biomanufacturing International Outsourcing /Offshoring to Lower-Cost Regions; Five Year Projection for Biomanufacturing International Outsourcing/ Offshoring to Lower-Cost Regions (2011-2026); Five Year Projection for Average Percentages of Biomanufacturing International Outsourcing/Offshoring to Lower-Cost Regions (2011-2026); Outsourcing to New Regions (2020 data); 7-9 DISCUSSION: OUTSOURCING AND OFFSHORING; Trends and Drivers of Outsourcing; Strategic Shifts in Outsourcing; Future Projections
CHAPTER 8: DISPOSABLES AND SINGLE-USE SYSTEMS IN BIOPHARMACEUTICAL MANUFACTURING: KEY TAKEAWAYS; 8-1 USE OF DISPOSABLES AND SINGLE-USE SYSTEMS; Background and Definitions; Disposables Applications in Biopharmaceutical Manufacturing; Trends in Disposable Applications (2006-2026); Average Annual Growth Rate for Disposables: 20 Years of Market Penetration and Usage; 20-Year Average Growth In Disposable Applications, Percentage-Point Gains Disposable Use by Stage of Production/Application; Use of Disposables: Biomanufacturers vs. CMOs; 8-2 LEACHABLES AND EXTRACTABLES; Issues Related to Leachables and Extractables (2018 data); 8-3 REASONS FOR INCREASING USE OF DISPOSABLES & SINGLE-USE SYSTEMS; Single Most Critical Reason for Increasing the Use of Disposables; 8-4 FACTORS THAT MAY RESTRICT USE OF DISPOSABLES; Factors that May Restrict Use of Disposables, 2026; Most Important Factors That May Restrict Use of Disposables (2006-2015, 2025-2026); Cell-Culture Problems due to Single-Use Devices (2021 vs. 2022); Recycling of Disposables (2020); 8-5 SINGLE-USE ADOPTION ISSUES; Evolution of SUS Adoption; Single-use Failures by Timeframe and SUS Type; Average Weeks Before Failures of Single-use Devices (2023-2026); 8-6 NEED FOR SINGLE-USE SENSORS, AND BIOREACTOR ATTRIBUTES; Single-Use Sensor Technologies (2012-2017, 2019, 2026); 8-7 SATISFACTION WITH SINGLE-USE DEVICE VENDORS (2008-2026); Single-Use Product Vendor Satisfaction Factors (2008-2026); Single-Use Attribute Importance Analysis; Single-Use Suppliers’ Issues (2013-2026); 8-8 SINGLE-USE OPERATIONS AND TRENDS; Percentage of Unit Operations that are Single-Use (2014-2026); Percentage of Single-Use Device Usage in Biomanufacturing; 8-9 DISCUSSION: SINGLE-USE BIOPROCESSING; Single-use Advantages; Growth in the Use of Single-use Systems; Downstream Single-use Systems Usage; CMOs’ Use of Single-use Equipment; Modular: The Next Trend after Single-Use?; Single-use Equipment Sourcing, Quality Issues, and L&E Testing
CHAPTER 9: DOWNSTREAM PURIFICATION: KEY TAKEAWAYS; 9-1 IMPACT OF DOWNSTREAM PROCESSING ON CAPACITY; Background and Definitions; Impact of Downstream Processing on Overall Capacity; Impact of Downstream Processing on Capacity, Biomanufacturers vs. CMOs; Impact of Downstream Processing on Capacity, U.S. vs. Western European Biomanufacturers; 9-2 SPECIFIC PURIFICATION STEP CONSTRAINTS; Background on Purification Processes in DSP; Changes in Impact on Capacity of Purification Steps (2008-2026); Specific Purification Step Constraints, U.S. vs. Western European Biomanufacturers; 9-3 DOWNSTREAM PURIFICATION ISSUES; Protein A and Alternatives (2022 data); Changes in Perception of Protein A and Alternatives (2009-2017, 2020-2022); 9-4 MAB PURIFICATION CAPACITY ESTIMATES; Upstream Production Titer vs. Max Capacity; Over-building of DSP Capacity to Handle Available Bioreactor Capacity; 9-5 NEW DOWNSTREAM PROCESSING TECHNOLOGIES; New Downstream Processing Solutions (2010-2026); New Downstream Processing Technologies; Biomanufacturers vs. CMOs; New Downstream Processing Technologies: U.S. vs. Western Europe; 9-6 IMPROVEMENTS TO DOWNSTREAM OPERATIONS; Drivers of Downstream Processing Bottlenecks; Improving Downstream Operations (2011-2019, 2025-2026); 9-7 FILL FINISH TRENDS; Background and Definitions; Fill-Finish Trends (2025); Recent Industry Trends; New Technology Implementation in Fill-Finish; Outsourcing Fill/Finish; 9-8 DSP Yield in Primary Process; 9-9 DISCUSSION: INDUSTRY TRENDS; Downstream Processing Solutions; Artificial Intelligence; Continuous Downstream Bioprocessing; Single-use systems; Membrane-based Filtration
CHAPTER 10: HIRING, EMPLOYMENT GROWTH, AND TRAINING IN BIOPHARMACEUTICAL MANUFACTURING: KEY TAKEAWAYS; Background and Definitions; 10-1 HIRING TRENDS; New Hires in Biopharmaceutical Manufacturing, 2026; Trends in New Hires, by Area (2008-2026); 10-2 FIVE YEAR TRENDS IN HIRING (2031); New Hires in Biopharmaceutical Manufacturing in Five Years (2031); 10-3 HIRING CHALLENGES TODAY; Areas Where Hiring Difficulties Exist in Biopharmaceutical Operations, 2026; Hiring Difficulties (2010-2026); U.S. and Western Europe Hiring Difficulties; 10-4 TRAINING IN BIOPHARMACEUTICAL MANUFACTURING; 10-5 DISCUSSION: STRATEGIES FOR SUCCESSFUL EMPLOYMENT GROWTH; Root Causes of the Persistent Talent Gap; Rapid Technology Evolution; Multidisciplinary Skillset; Insufficient Hands-On Training; Supply–Demand Mismatch; Retention Challenges; Strategic Training; Attractive Career Paths
CHAPTER 11: NEW METHODS: CONTINUOUS AND PROCESS: INTENSIFICATION, CELL AND GENE THERAPIES; KEY TAKEAWAYS; INTRODUCTION TO INNOVATIVE BIOPROCESSING; Background and Definitions; Benefits of Cell and Gene Therapies; Benefits of Continuous Bioprocessing and Perfusion; 11-1 FUTURE ADOPTION OF CONTINUOUS BIOPROCESSING AND PROCESS INTENSIFICATION; Future of Continuous Bioprocessing in 2026; Future of Continuous Bioprocessing (2018-2025); 11-2 PERFUSION OPERATIONS AND CONTINUOUS BIOPROCESSING; OPERATIONAL ISSUES; Perfusion vs. Batch Fed Bioprocessing – Areas of Much Bigger Concern; Perfusion Operation Issues (2010-2014, 2016, 2020, 2023-2025); Evaluating or Considering CBP technologies (Upstream) Over the Next 12 Months (2016-2025); Evaluating or Considering CBP technologies (Downstream) Over the Next 12 Months (2016-2025); Continuous Bioprocessing and Perfusion Trends; 11-3 AUTOMATION IMPLEMENTATION; Demand for Automation; Comparison of Implementation Plans (2009-2013, 2022-2026); The Role of Automation in Supporting Continuous Bioprocessing; Factor Inhibiting Greater Automation (2026); 11-4 ARTIFICIAL INTELLIGENCE (AI) ACTIVITIES; Artificial Intelligence in Biomanufacturing; Activities Considered Using Artificial Intelligence (AI) in the Next 2 Years (2028); Challenges in Implementation of Artificial Intelligence (2026); Activities Using Artificial Intelligence (AI) Today vs in the Next 2 Years (2028); 11-5 CELL AND GENE THERAPY PLATFORMS; Cell and Gene Therapy Manufacturing: A Catalyst for Innovation; Cell and Gene Therapy Manufacturing Trends; Cell Therapy Manufacturing Improvements, Systems, Platforms, and Infrastructure (2019-2025); Gene Therapy Manufacturing Improvements, Systems, Platforms, and Infrastructure (2019-2025); Advanced Therapy (Cell or Gene Therapy) GMP and Commercial Manufacturing (2020-2025); Cell Therapy Capacity Plans for In-House Bioprocessing Facilities: Five Year Estimates (2023-2025); Cell Therapies Commercial Manufacturing Scales (2021); Gene Therapy Vectors and Products Commercial Manufacturing Scales (2021); 11-6 DISCUSSION: FUTURE OF BIOMANUFACTURING; Looking Ahead: Industry Considerations and Strategic Imperatives
CHAPTER 12: SUPPLIERS TO BIOPHARMACEUTICAL MANUFACTURING AND LIFE SCIENCES: KEY TAKEAWAYS; 12-1 DEMOGRAPHICS; Background and Definitions; Areas of Involvement; Location of Vendor Sales; Vendor / Supplier Respondents’ Primary Job; 12-2 GROWTH RATE OF SALES BY SUPPLIERS; Average Annual Vendor Sales Growth Rate; Distribution of Growth Rates; Average Industry Growth Rate, By Segment; Average Industry Growth Rate, By Segment (2007-2026); Supplier Annual Sales, Distribution; 12-3 BUDGET ISSUES AND PROBLEMS FACED BY INDUSTRY SUPPLIERS; Budget planning requires long-term projections for sales, segment growth and other trends; Budget Challenges in 2026; Vendor Average Pricing Changes; Vendor Projected 2026 Pricing Changes; 12-4 PROBLEMS CLIENTS HAVE WITH THEIR VENDORS; Quality of Business Relationships with Suppliers; Quality of Business Relationships with Clients; Supplier Values:; Facility / Customer Values:; CMOs Problems with Their Clients (2018 data); Quality Problems Traced to Vendors (2018 data); 12-5 IMPACTS OF COVID-19 ON SUPPLIERS’ ACTIVITIES; Impact of COVID-19 Pandemic on Vendors, Percent Indicating an INCREASE in COVID-Related Factors (2021-2023); Post COVID Impact on Suppliers: Permanent Changes on Business Operations Biopharma Vendor Business Trends; Biopharma Vendor Business Trends (2010-2026); 12-6 VENDORS’ PRODUCTS AND SERVICES; New Technology Areas in Development by Vendors; Suppliers’ R&D Spending/Budgets for New Products/Services; 12-7 SALES STAFF TRAINING; Areas where Training May Help Sales Staff Perform, Trends (2010-2026); Client Demands of Vendors, Service and Support (2012-2026); 12-8 BIOPHARMA VENDORS’ FINANCIAL OUTLOOK FOR 2026; 12-9 CMO PRICING CHANGES FOR BIOPHARMACEUTICAL SERVICES; 12-10 DISCUSSION: BIOPHARMA SUPPLIERS; Vendor and Industry Growth; Biopharma Suppliers in Emerging Regions
FIGURES AND TABLES: Fig 0.1: Area of Primary Involvement in Biopharmaceutical Manufacturing (2010-2026); Fig 0.2: Respondents’ Job Responsibilities (2011-2026); Fig 0.3: Facility Location, 2026; Fig 0.4: Facility Location, by Region, 2026; Fig 0.5: Biopharmaceutical Manufacturing Systems, Trends (2007-2026); Fig 0.6: Phase of Development of Surveyed Respondents (2006-2026); Fig 0.7: Phase of Development of Surveyed Respondents, U.S. vs. Western Europe (2026).13; Fig 0.8: Distribution of Employees at Facility and Organization, 2026; Fig 0.9: Distribution of Total Batches Run at Facility in Past 12 Months, by Scale of Production (2026); Fig 0.10: Distribution of Largest SINGLE-USE Bioreactor Capacity (2017-2026); Fig 0.11: Average SINGLE-USE Bioreactor Volume (Liters) (2017-2026); Fig 0.12: Distribution of Largest STAINLESS Bioreactor Capacity (2017-2026); Fig 0.13: Average ‘Largest’ Stainless Steel Capacity (L) (2017-2026); Fig 1.1: Top 50 Biopharmaceutical Products, Percentage of Total Market Revenue; Fig 2.1: Numbers of Recombinant and Non-Recombinant Biopharmaceuticals Approved by FDA Since 1982 (1982-2025); Fig 2.2: Number of Facilities, both Recombinant and Synthetic (SPPS), Peptide Therapeutics, All Scales, 2026, Percent; Fig 2.3: Global Capacity for Synthetic (SPPS), Commercial-scale Peptide Therapeutics, 2026, Percent; Fig 2.4: Factors Creating Future Capacity Constraints, Biomanufacturers vs. CMOs, 2026, Percent; Fig 3.1: SINGLE Most Important Biomanufacturing Trend or Operational Area (2014-2026); Fig 3.2: Novel Bioprocessing Systems/Innovations to Evaluate in Next 12 Months (2018-2026); Fig 3.3: Novel Bioprocessing Systems/Innovations to Evaluate in Next 12 Months (Biomanufacturers vs. CMOs), 2026; Fig 3.4: Operational Changes Due to Recent Global Economics, 2026; Fig 3.5: Operational Changes Due to Recent Global Economics (2010 - 2012, 2022-2026); Fig 3.6: Operational Changes Due to Recent Global Economics; Biomanufacturers vs. CMOs, 2026; Fig 3.7: Operational Changes Due to Recent Global Economics; U.S. vs. Western Europe, 2026; Fig 3.8: Biomanufacturers’ Budget Shifts, 2026; Fig 3.9: Approximate Average Change in Biomanufacturers’ Budgets, 2026; Fig 3.10: Average Biomanufacturers’ Budget Changes (2009-2026); Fig 3.11: New Expenditures Focus Areas, 2026; Fig 3.12: New Expenditures Focus Areas (2020-2026); Fig 3.13: New Product Development-Upstream Focus Areas, 2026; Fig 3.14: Upstream New Product Development Areas Cited Where Suppliers Should Focus Development Efforts (2010-2026); Fig 3.15: Downstream New Product Development Areas Cited Where Suppliers Should Focus Development Efforts, 2026; Fig 3.16: New Product Development – Downstream Focus Areas (2010-2026); Fig 3.17: New Product Development – General Focus Areas, Biomanufacturers & CMOs, 2026; Fig 3.18: New Product Development – General Focus Areas (2010-2026); Fig 3.19: Top 10 New Product Development Areas of Interest: Biomanufacturers vs. CMOs, 2026 Fig 3.20: Top 10 New Product Development Areas of Interest: U.S. vs. Western Europe vs. ROW, 2026; Fig 3.21: Factors in Biomanufacturing Performance Creating “Significant” or “Some” Improvements, 2026; Fig 3.22: Factors in Biomanufacturing Performance Creating “Significant” or “Some” Improvements (2010-2015, 2025-2026); Fig 3.23: Factors in Biomanufacturing Performance Creating “Significant” or “Some” Improvements: Biomanufacturers vs. CMOs, 2026; Fig 3.24: Factors in Biomanufacturing Performance Creating “Significant” or “Some” Improvements: US vs. Western Europe vs. ROW, 2026; Fig 3.25: Cost-Cutting Changes: Actions Undertaken During “Past 12 Months” Comparing (2011-2016, 2019-2024); Fig 3.26: Cost-Cutting Changes, Outsourced Jobs, by Segment, (2011-2016, 2019-2024); Fig 3.27: Factors That Will Have the Greatest Impact on REDUCING YOUR COST OF GOODS for Biotherapeutic Products (2020-2024); Fig 3.28: Distribution, Average Cost per Gram for PRIMARY Recombinant Protein, 2026; Fig 3.29: Distribution, Average Cost per Gram for PRIMARY Recombinant Protein (2017-2026); Fig 3.30: Biomanufacturing Assay “Areas” Urgently Requiring New, Improved Testing Methods (2011-2015, 2018-2019, 2024, 2026); Fig 3.31: Biomanufacturing Assay ‘Areas’ Urgently Requiring New, Improved Testing Methods; Biomanufacturers vs. CMOs, 2026; Fig 3.32: Biomanufacturing Assay ‘Areas’ Urgently Requiring New, Improved Testing Methods; US vs. Western Europe, 2026; Fig 3.33: Largest Commercial-Scale Bioreactor Expected in the Next Two Years (2028); Fig 3.34: Top Options for Bioreactor Platforms at Commercial Scale, 2024; Fig 3.35: Top Options for Bioreactor Platforms at Commercial Scale (2021-2024); Fig 3.36: Distribution of Largest Single-Use Bioreactor Capacity to Purchase in Next Two Years (2022, 2025-2026); Fig 3.37: Distribution of Largest Stainless Steel Bioreactor Capacity to Purchase in Next Two Years (2022, 2025-2026); Fig 4.1: Capacity Utilization, By System, 2026; Fig 4.2: Capacity Utilization, By System (2006-2026); Fig 4.3: Change in Capacity Utilization, CAGR (2006-2026); Fig 4.4: Capacity Utilization, By System, Biomanufacturers vs. CMOs, 2026; Fig 4.5: Availability of CMO/CDMO Capacity (2024-2026); Fig 4.6: Capacity Utilization, By System, U.S. vs. Western Europe, 2026; Fig 4.7: Western European vs. US Biomanufacturers’ Average Capacity Utilization (2012-2026); Fig 4.8: Current Production Capacity Distribution, Mammalian Cell Culture, 2026; Fig 4.9: Production Capacity Distribution, Mammalian Cell Culture (2010-2026); Fig 4.10: Current Production Capacity Distribution, Microbial Fermentation, 2026; Fig 4.11: Current Production Capacity Distribution, Microbial Fermentation (2010-2026); Fig 4.12: Current Production Capacity Distribution, Cell Therapy, 2026; Fig 4.13: Production Capacity Distribution, Cell Therapy (2020-2026); Fig 4.14: Current Production Capacity Distribution, Gene Therapy, 2026; Fig 4.15: Production Capacity Distribution, Gene Therapy (2020-2026); Fig 4.16: Bioprocessing Concentration, Capacity Data, 2026; Fig 4.17: Range of Titers for mAbs Obtained at Various Production Scales, Distribution, 2026; Fig 4.18: Average mAb Titer Trend (2008-2026); Fig 5.1: Capacity Constraints, by Stage of Production, 2026; Fig 5.2: Capacity Constraints ‘Today’ (2004-2026); Fig 5.3: Capacity Constraints Trends (2004-2026); Fig 5.4: Capacity Constraints, Biomanufacturers vs. CMOs, 2026; Fig 5.5: Capacity Constraints, U.S. vs. Western Europe, 2026; Fig 5.6: Expectations of Capacity Constraints by Stage of Production: Five-year Projections (by 2031); Fig 5.7: Expectations of Capacity Constraints: Five-year Projections (2004-2026); Fig 5.8: Expectations of Capacity Constraints: Five-year Projections (Trend Line) (2004-2026); Fig 5.9: Five-year Projections for Capacity Constraints: Biomanufacturers vs. CMOs (2031); Fig 5.10: Five-year Projections for Capacity Constraints: U.S. vs. Western Europe (2031); Fig 5.11: Factors Creating Future Capacity Constraints in Five Years (2031); Fig 5.12A: Factors Creating Future Capacity Constraints in Five Years (2008-2026); Fig 5.12B: Factors Creating Future Capacity Constraints in Five Years (2008-2026); Fig 5.13: Factors Creating Future Capacity Constraints: Biomanufacturers vs. CMOs, 2026.224; Fig 5.14: Factors Creating Future Capacity Constraints, U.S. vs. Western Europe Biomanufacturers, 2026; Fig 5.15: Key Areas to Address to Avoid Capacity Constraints, 2026; Fig 5.16A: Key Areas to Address to Avoid Capacity Constraints (2006-2026); Fig 5.16B: Key areas to Address to Avoid Capacity Constraints (2006-2026); Fig 5.17: Key Areas to Address to Avoid Capacity Constraints; Biomanufacturers vs. CMOs, 2026; Fig 5.18: Key Areas to Address to Avoid Capacity Constraints; U.S. vs. Western Europe, 2026; Fig 5.19: Average Time (weeks) Between Batch Failures (2009-2026); Fig 5.20: Batch Failure Frequency Distribution (2009-2026); Fig 5.21: Average Rates of Failure, by Primary Cause, and Phase of Manufacture, 2026; Fig 5.22: Average Rates of Failure, by Primary Cause, and Phase of Manufacturing (Commercial Manufacture) (2009-2026); Fig 5.23: Average Rates of Failure, by Primary Cause, and Phase of Manufacturing (“Clinical” Scale) (2009-2026); Fig 5.24: Global Quality Supply Management (2011-2013, 2022-2023); Fig 5.25: Global Quality Supply Management, Biomanufacturers vs. CMOs, 2023; Fig 5.26: Global Quality Supply Management (U.S. vs. W. Europe), 2023; Fig 5.27: Addressing Supply Chain Security (2023-2026); Fig 6.1: Industry Average Planned Production Increase: Five Year Estimates (2031); Fig 6.2: Planned Future Capacity Expansion: Five Year Estimates (2009–2031); Fig 6.3: Percentage of Respondents Projecting Production Increases over 100%: Five Year Trend (2031); Fig 6.4: Average Planned Future Capacity Expansion: Five-Year Estimates, Biomanufacturers vs. CMOs, by 2031; Fig 6.5: Average Planned Future Capacity Expansion: Five-Year Estimates, U.S. vs. Western Europe, by 2031; Fig 7.1: Current Percent Production Outsourced; by System, 2026; Fig 7.2: Biopharmaceutical Manufacturing Facilities Outsourcing NO Production (2006-2026); Fig 7.3: Current Percent Respondents Outsourcing up to 50% of Production, by System, 2009-2026; Fig 7.4: Biomanufacturers’ Outsourcing, Five Year Projections, by System (2031); Fig 7.5: Five-year Projections: % Biotherapeutic Manufacturers Planning to Outsource at Least Some Production; Projections made 2007-2026; Fig 7.6: Biomanufacturers Outsourcing Some Activity Today, 2026; Fig 7.7A: Percent of Biomanufacturers Outsourcing at Least Some Activity Today (2010-2026); Fig 7.7B: Percent of Biomanufacturers Outsourcing at Least Some Activity Today (2010-2026); Fig 7.8: Outsourcing Activities Projected to be Done at ‘Significantly Higher Levels’ in 2 Years (2026); Fig 7.9A: Outsourcing Activities Projected to be Done at ‘Significantly Higher Levels’ in 2 Years, Trends (2010-2026); Fig 7.9B: Outsourcing Activities Projected to be Done at ‘Significantly Higher Levels’ in 2 Years, Trends (2010-2026); Fig 7.10: Estimated Average Percentage of Activity Outsourced, by Facilities Today, 2026; Fig 7.11A: Estimated Average Percent of Activity Outsourced by Facilities (2010-2026); Fig 7.11B: Estimated Average Percent of Activity Outsourced by Facilities (2010-2026); Fig 7.12: Change in Spending on Outsourcing for R&D or Manufacturing, Next 12 months (2012-2026); Fig 7.13: Average Change in Outsourcing Spending by Facilities, (2013-2026), with 2-year moving average; Fig 7.14: Outsourcing Issues: BioManufacturing by Contract Manufacturing Organizations, 2026; Fig 7.15: ‘Very Important’ Issues for Considering Outsourcing to CMOs, Percentage Point Shifts Over Time (2006-2018, 2025-2026); Fig 7.16: U.S. BioSecure Act INFLUENCE Choice of Commercial-scale Contract Manufacturers (CMOs) or Outsourcing Vendors, 2025; Fig 7.17: Percent Indicating USA as Likely or Strong Likely Selection for INTERNATIONAL (non-US respondents) Outsourcing Over Next Five Years, 2009-2026 (targeting 2031); Fig 7.18: Country Selections for International Outsourcing/Capacity Expansion Over Next Five Years, 2031; Fig 7.19A: Country Selections for “Possible” International Outsourcing/Capacity Expansion Over Next Five Years (2016-2026); Fig 7.19B: Country Selections for “Possible” International Outsourcing/Capacity Expansion Over Next Five Years (2016-2026); Fig 7.20A: U.S. Respondents Considering International Country as “Possible” International Outsourcing Destination, over Next Five Years (2009-2026); Fig 7.20B: U.S. Respondents Considering International Country as “Possible” International Outsourcing Destination, over Next Five Years (2009-2026); Fig 7.21: U.S. Respondents Considering Country as “Strong likelihood” or “Likelihood” as Outsourced Capacity Destination, Next Five Years (2031); Fig 7.22A: Western European Respondents Considering Country as “Possible” Outsourcing Destination, Next Five Years, (2009-2026); Fig 7.22B: Western European Respondents Considering Country as “Possible” Outsourcing Destination, Next Five Years, (2009-2026); Fig 7.23: Western European Respondents Considering Country as ‘Strong likelihood’ or ‘Likelihood’ as Outsourced Capacity Destination, over Next Five Years (2031); Fig 7.24: Percent of Biomanufacturing Operations Offshored (International Outsourcing) to Lower-Cost Regions Within Five Years (2031); Fig 7.25: Percent of Biomanufacturers Performing at Least “Some” International Outsourcing/Offshoring to Lower-Cost Regions Over Next Five Years (2011-2026); Fig 7.26: Estimated Average Percentage of Operations to be Done as International Outsourcing/ Offshoring to Lower-Cost Regions During Next Five Years (2011-2026); Fig 8.1: Usage of Disposables in Biopharmaceutical Manufacturing, Any Stage of R&D or Manufacture, 2026; Fig 8.2A: Usage of Disposables in Biopharmaceutical Manufacturing, Any Stage of R&D or Manufacture (2006-2026); Fig 8.2B: Usage of Disposables in Biopharmaceutical Manufacturing, Any Stage of R&D or Manufacture (2006-2026); Fig 8.3: Average Annual Growth Rate, Disposables (2006-2026); Fig 8.4: 20-Year Percentage-Point Increase in First Usage of Disposables (2006-2026); Fig 8.5: Usage of Disposables in Biomanufacturing by Stage of Manufacture (R&D–Commercial), 2026; Fig 8.6: Usage of Disposables in Biopharmaceutical Manufacturing: Biomanufacturers vs. CMOs, 2026; Fig 8.7: Reasons for Increasing Use of Disposable System Components, 2026; Fig 8.8: Reasons for Increasing Use of Disposable System Components, 2006-2015, 2026; Fig 8.9: Reasons for Restricting Use of Disposables, 2026; Fig 8.10: Factors Restricting Use of Disposables (2006-2015, 2025-2026); Fig 8.11: Time Since Facility’s Last Failure of Single-use Devices and Equipment, 2026; Fig 8.12: Average Weeks Before Failure of Single-use Devices and Equipment (2023-2026); Fig 8.13: Need for Improved Single-Use Sensors, 2012-2017, 2019, 2026; Fig 8.14: Single-Use Product Vendor Satisfaction Factors (2008-2026); Fig 8.15: Importance of Single-Use Product Attributes vs. Level of Vendor Satisfaction, 2026; Fig 8.16: Percentage Point Gap between Importance of SUS Product Attributes and Level of Satisfaction (2013-2026); Fig 8.17: Estimated Percentage of Facilities’ Unit Operations that Are “Single-Use” (2014-2026); Fig 8.18: Distribution of Responses, % Single-Use Devices in Biomanufacturing, 2026; Fig 9.1: Impact of Downstream Processing on Overall Capacity (2008-2026); Fig 9.2: Impact of Downstream Processing on Overall Capacity; Biomanufacturers vs. CMOs, 2026; Fig 9.3: Impact of Downstream Processing on Overall Capacity; U.S. vs. Western Europe, 2026; Fig 9.4: Impact on Capacity of Depth, Chromatography and UF Purification Steps, 2026; Fig 9.5: Impact on Capacity of Purification Steps: Experiencing at ‘Significant’ or ‘Severe’ Constraints (2008-2026); Fig 9.6: Impact on Capacity of Purification Steps, U.S. vs. Western Europe, 2026; Fig 9.7: Issues Regarding Protein A Usage (2022); Fig 9.8: Issues Regarding Protein A Usage (2009-2017, 2020-2022); Fig 9.9: mAb Operations: Upstream Production Titer (Distribution of Responses (2014 -2016, 2018-2026); Fig 9.10: Bioreactor Output at which DOWNSTREAM Purification Train Becomes Bottlenecked (2014-2016, 2018-2026); Fig 9.11: New Downstream Processing Solutions, 2026; Fig 9.12A: New Downstream Processing Solutions Comparison (2010-2026); Fig 9.12B: New Downstream Processing Solutions Comparison (2010-2026); Fig 9.13: New Downstream Processing Solutions: Biomanufacturers vs. CMOs, 2026; Fig 9.14: New Downstream Processing Solutions: U.S. vs. Western Europe, 2026; Fig 9.15: Improving Downstream Operations, (2011-2019, 2025-2026); Fig 9.16: Most Important Fill-Finish Trends (2015-2017, 2025); Fig 9.17: Novel Fill-Finish Technology Implementation Plans within 24 Months (2015-2017, 2025); Fig 9.18: Average Downstream Processing (DSP) Yield; Fig 9.19: Percent Point Change in DSP Yield - Past 2 Years vs Today; Fig 10.1: New Hires in Biopharmaceutical Manufacturing, 2026; Fig 10.2: Estimated % of Hiring in Biopharmaceutical Manufacturing, by Operational Area, (2008-2026); Fig 10.3: New Hires in Biopharmaceutical Manufacturing in Five Years (2031); Fig 10.4: Areas Where Hiring Difficulties Exist in Biopharmaceutical Operations, 2026; Fig 10.5A: Areas Where Hiring Difficulties Exist in Biopharmaceutical Operations (2010-2026); Fig 10.5B: Areas Where Hiring Difficulties Exist in Biopharmaceutical Operations (2010-2026); Fig 10.6: Areas Where Hiring Difficulties Exist in Biopharmaceutical Operations, U.S. vs. Western Europe, 2026; Fig 10.7: Skills or Hands-On Training Required in NEW HIRES in GMP Bioprocessing (2023-2026); Fig 11.1: Future of Continuous Bioprocessing and Process Intensification, 2026; Fig 11.2: Future of Continuous Bioprocessing and Process Intensification (2018-2025); Fig 11.3: Concerns Over Perfusion Processes vs. Batch-fed Processes in Bioprocessing, 2025; Fig 11.4: Perfusion Operations Issues (2011 – 2014, 2016, 2020, 2023-2025); Fig 11.5: Facilities Evaluating CBP Technologies Over the Next 12 Months (Upstream) (2016-2025); Fig 11.6: Facilities Evaluating CBP Technologies Over Next 12 months (Downstream) (2016-2025); Fig 11.7: Automation Technologies Implemented/to be Implemented in 2026; Fig 11.8: Automation Technologies to be Implemented; Comparing (2009 - 2013, 2022-2026); Fig 11.9: Most Common Factors Inhibiting Greater AUTOMATION of your Facility’s Bioprocessing Today, 2026; Fig 11.10: Bioprocessing Activities Using AI in Next 2 Years (2028); Fig 11.11: Biggest Problems/Hurdles to Facility’s Implementing Artificial Intelligence (AI) tools in Bioprocessing, 2026; Fig 11.12: Respondents Currently Using or Considering Artificial Intelligence (AI) Application/Approaches at Bioprocessing Facility: TODAY vs 2 YEARS:; Fig 11.13: Most Needed Cell Therapy Manufacturing Improvements, Systems, Platforms, and Infrastructure (2019-2025); Fig 11.14: Most Needed Gene Therapy Manufacturing Improvements, Systems, Platforms and Infrastructure (2019-2025); Fig 11.15: Cell or Gene Therapy Plans for GMP and Commercial Manufacturing (2020-2025); Fig 11.16: Cell Therapy Capacity Plans for In-House Bioprocessing Facilities Next Five Years (2030); Fig 12.1: Area of Biopharmaceutical Involvement, Vendor, 2026; Fig 12.2: Area of Biopharmaceutical Involvement, Vendor (2010-2026); Fig 12.3A: In Which Geographic Regions/Countries Does Your Company Currently Actively Sell (2008-2026); Fig 12.3B: In Which Geographic Regions/Countries Does Your Company Currently Actively Sell (2008-2026); Fig 12.4: Vendor Respondents’ Primary Job Function, 2026; Fig 12.5: Average Annual Vendor Sales Growth Rate (2007-2026); Fig 12.6: Biopharmaceutical Supply Market Segment Sales Growth Distribution, 2026; Fig 12.7: Average Annual Vendor Segment Sales Growth Rates, 2026; Fig 12.8: Average Annual Vendor Sales Growth Rate, by Segment (2007-2026); Fig 12.9: Vendors’ Approx. Annual Sales to Biopharmaceutical Segment % (2012-2026); Fig 12.10: Vendors’ Average Budget Change, 2026; Fig 12.11: Vendors’ Average Budget Change, Summary (2009-2026); Fig 12.12: Vendors’ Average Pricing Changes, Last Year (2026); Fig 12.13: Vendors’ Average Pricing Changes, 2009-2025 Actual and 2026 Projected; Fig 12.14: ‘Most Important’ Factors to Measure The ‘Quality’ of Business Relationships with Suppliers, BIOMANUFACTURERS’ PERSPECTIVE (2022-2026); Fig 12.15: ‘Most Important’ Factors to Measure The ‘Quality’ of Business Relationships with Suppliers, SUPPLIERS vs. FACILITIES (2022-2026); Fig 12.16: Impact of COVID-19 Pandemic on Vendors, Percent Indicating an INCREASE in COVID-Related Factors (2021-2023); Fig 12.17: Permanent Changes caused by Pandemic on Your Business Operations (2024 vs 2025); Fig 12.18: Biopharma Business and Marketing Plans, 2026; Fig 12.19: Biopharma Business and Marketing Plans (2010-2026); Fig 12.20A: Top New Technologies or New Product Development Areas (2011-2026); Fig 12.20B: Top New Technologies or New Product Development Areas (2011-2026); Fig 12.20C: Top New Technologies or New Product Development Areas (2011-2026); Fig 12.21: R&D Spending/Budgets for New Products/Services, 2026; Fig 12.22: Approximate Average Annual R&D Spending/Budget for New Products/Services (2017-2026); Fig 12.23: Areas Where Training is Considered as Needed or Very Much Needed, All Vendor Respondents (2010-2026); Fig 12.24: Client Demands of Vendors, Service and Support (2012-2026); Fig 12.25: Vendors Views of Financial (Sales) Outlook for Next Year (2011-2026); Fig 12.26: Average CMOs Service Price Shifts over the “Past 12 Mo.” (2010-2012, 2018-2026); Fig 12.27: CMOs Service Price Shifts Over Past 12 Months, Distribution, 2026
TABLES: Table 0.1: Areas of Biopharmaceutical Manufacturing Operations (2018-2026); Table 1.1: Worldwide Revenue of Biopharmaceuticals ($USD billions); Table 1.2: Number of Biopharmaceutical Products in U.S. and European Markets, 2025-2026; Table 1.3: Global Market for Top 50 Biopharma Products in (2024-2025, $USD Million); Table 1.4: Top 50 Biopharmaceutical Products vs Total Market Size (%) $million; Table 1.5: Bioprocess Related Industry Expenditures on Manufacture of Biotherapeutics (estimated $USD, billions); Table 1.6: Summary of Worldwide Biopharmaceutical Revenue Growth by Product Class, 2007 and 2025; Table 2.1: Biopharmaceuticals Approved by FDA, 2025; Table 2.2: Biopharmaceuticals Approved by FDA in 2026 (Till May’2026); Table 2.3: Facility Takeovers Involving CDMOs; Table 2.4: M&A Transactions Involving CDMOs; Table 3.1A: Areas of Significant Projected Budget Percentage Increases for Biomanufacturing (2011-2026); Table 3.1B: Areas of Significant Projected Budget Percentage Increases for Biomanufacturing (2011-2026); Table 4.1: Regional Distribution of Total Worldwide Average Capacity*; Table 4.2: Leading Biopharma Company Capacity Estimates, 2026; Table 4.3: Bioprocessing CMOs, Their Number of Facilities Worldwide and Estimated Total Capacity*; Table 4.4: Compound Annual Change in mAb Titers (2008-2026); Table 5.1: Severe or Significant Capacity Constraints, by Stage of Production (2009-2026); Table 5.2: Severe and Significant Capacity Constraints Today, U.S. vs. W. Europe (2010-2026); Table 5.3: Average Rates of Failure, by Primary Cause, and Phase of Manufacture (2017-2026); Table 6.1: U.S. Biomanufacturers’ Five-Year Projected Capacity Increases, by System (2008-2026); Table 6.2: Western European Biomanufacturers’ Five-Year Projected Capacity Increases, by System (2008-2026); Table 7.1: Percentage of U.S.-based Respondents Indicating Country as a ‘Strong likelihood’ or ‘Likelihood’ as Outsourcing Destination (2009-2026); Table 7.2: Percent of Western European-based Respondents Indicating International Countries as a ‘Strong likelihood’ or ‘Likelihood’ as Outsourcing Destination (2011-2026); Table 9.1: Percent of Biomanufacturers vs. CMO Facilities Experiencing “Serious” or “Some” Capacity Problems due to Downstream Processing (2008-2026); Table 9.2: Percent of U.S. vs. Western Europe Facilities Experiencing ‘Serious’ Capacity Problems due to Downstream Processing (2009-2026); Table 9.3: Percent U.S. vs. Western Europe Facilities Not Expecting to see Bottlenecks due to Downstream Processing (2008-2026); Table 9.4: Upstream Production Titer vs. Max Capacity (2018-2026); Table 12.1: Average Vendor Sales and Technical Training Days (2011-2013, 2019-2021)

Pricing

Currency Rates

Department License Fulfilled by Publisher $3,150

How Do Licenses Work?

Request A Sample

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.

Chat Now